MRI Scans Clinical Trial
Official title:
Comparison of New MRI Methods for Quantitative Assessment of Myocardial Perfusion With Quantitative PET Perfusion Imaging
Verified date | September 2020 |
Source | University of Utah |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This work seeks to develop, evaluate and use new MRI methods for non-invasive quantitative assessment of myocardial perfusion and perfusion reserve (MPR), and to compare with quantitative PET imaging.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 12, 2019 |
Est. primary completion date | June 12, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- Inclusion Criteria: - All participants will be over the age of 18 and able to provide consent - Both healthy and subjects with cardiac disease (including atrial fibrillation but not required) will be recruited. - Exclusion Criteria: - Critically ill patients, patients on ventilators, patients with unstable angina or with hypotension, asthmatics, and other patients whose medical care or safety may be at risk from undergoing an MRI examination will be excluded. - Patients with claustrophobia will also be excluded from the study if this cannot be controlled with standard methods (valium or benadryl). - Patients with contraindication to MRI (pacemaker, metal implants, or certain types of heart valves), - pregnant patients, minors, mentally disabled patients and prisoners will be excluded from this study. (All criteria apply to patients and normal volunteers). - Gadolinium nephrotoxicity will be addressed by having patients with abnormal kidney function (GFR<30) excluded from the study due to the (very small) risk associated with gadolinium contrast agents. This threshold may be modified, depending on practices determined by the Radiology Department and the IRB. - Patients with a known allergy or contraindication to Adenosine and/or Regadenoson will be excluded from stress (hyperemia) cohorts. - All participants that will receive a stress agent will refrain from consuming caffeine for at least 12 hours prior to each study |
Country | Name | City | State |
---|---|---|---|
United States | University of Utah, Radiology Research | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Myocardial perfusion values from MRI | Myocardial perfusion in segments and coronary territories will be computed in ml/min/g from the dynamic MRI data. The perfusion values will be compared to PET data to determine how similar the values are. | The scan will take ~1-2 hours. The MRI will be done within 2 months of the PET scan. | |
Primary | Myocardial perfusion values from PET | Myocardial perfusion in segments and coronary territories will be computed in ml/min/g from the dynamic PET data. The perfusion values will be compared to MRI data to determine how similar the values are. | The scan will take ~1-2 hours. The PET scan will be done within 2 months of the MRI. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04448600 -
Bone Conduction Implant and MRI
|
||
Recruiting |
NCT04600115 -
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
|
Early Phase 1 | |
Recruiting |
NCT03891511 -
TMJ Fibrocartilage Detection Using MRI
|
||
Not yet recruiting |
NCT04871555 -
Structural Cartography of the Insula in Temporal Epilepsy Patients
|
||
Completed |
NCT02318550 -
Registry of Patients for MRI With Non-MRI Conditional Pacemakers and ICD Non-MRI Conditional Pacemakers and ICD
|
||
Recruiting |
NCT04171635 -
Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy
|